Company intelligence / Profile preview

iPierian

South San Francisco, California, United Statesbms.com ↗

Ownership: Private
Development stage: Preclinical

Overview

iPierian developed a proprietary iPSC-based platform to model neurodegenerative diseases and discover novel therapeutic targets. Its lead asset, IPN007—a monoclonal antibody targeting secreted Tau—showed strong preclinical data for tauopathies such as PSP and Alzheimer’s. The company was acquired by Bristol Myers Squibb in April 2014 before entering clinical trials; thus, no clinical results were published independently by iPierian.

Therapeutic areas: Neurology
Modalities: Monoclonal antibodies (mAbs)Induced pluripotent stem cells (iPSCs)
Industry: Biotech

Drug pipeline

1 asset

IPN007

Pre-clinical

Indications: Progressive supranuclear palsy

Beyond the preview

Go deeper on iPierian.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iPierian.

Explore the full profile